Retrieve available abstracts of 179 articles: HTML format
Single Articles
June 2025
SONG Y, Deng B, Long CA, Li Q, et al Priming or Boosting P. falciparum Transmission Blocking Responses with
Recombinant Vaccines or Gametocyte Extract.
J Infect Dis. 2025 Jun 12:jiaf318. doi: 10.1093. PubMedAbstract available
KNOX JJ, Lee I, Blumberg EA, Rosenfeld AM, et al B-Cell Subset Representation Predicts SARS-CoV-2 Vaccine Response in Solid Organ
Transplant Recipients.
J Infect Dis. 2025 Jun 3:jiaf250. doi: 10.1093. PubMedAbstract available
NAYAGAM SN, Coote W, Carroll MT, Toh ZQ, et al Differentiating SARS-CoV-2 antibody responses between infection and vaccination:
challenges for epidemiological research.
J Infect Dis. 2025 Jun 3:jiaf295. doi: 10.1093. PubMed
May 2025
BAUM HE, Santopaolo M, Francis O, Milodowski EJ, et al Hybrid B- and T-Cell Immunity Associates With Protection Against Breakthrough
Infection After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in
Avon Longitudinal Study of Parents and Children (ALSPAC) Participants.
J Infect Dis. 2025 May 20:jiaf246. doi: 10.1093. PubMedAbstract available
ZHU S, Quint J, Leon T, Sun M, et al Estimating Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza
Using Linked Public Health Information Systems, California, 2023-2024 Season.
J Infect Dis. 2025 May 13:jiaf248. doi: 10.1093. PubMedAbstract available
RUBENS JH, Brockhurst JK, Ghimire S, Wu J, et al Safety, immunogenicity, and protective efficacy in rhesus macaques of a novel
recombinant hemagglutinin protein measles virus vaccine.
J Infect Dis. 2025 May 13:jiaf244. doi: 10.1093. PubMedAbstract available
ABDELKADER S, Jefferson AA Trust, A Key to Counter Vaccine Hesitancy.
J Infect Dis. 2025 May 8:jiaf239. doi: 10.1093. PubMed
Correction to: Relative Effectiveness and Waning of a Third Dose of mRNA COVID-19
Vaccine in Medicare Beneficiaries Aged 65 Years and Older during the BA.1/BA.2
Omicron Period.
J Infect Dis. 2025 May 6:jiaf137. doi: 10.1093. PubMed
April 2025
LAI SW, Liao KF Herpes zoster vaccine and cardiovascular disease risk.
J Infect Dis. 2025 Apr 30:jiaf229. doi: 10.1093. PubMed
XU X, Ray I, Tang E, Arnold BF, et al Authors' reply to Herpes zoster vaccine and cardiovascular disease risk.
J Infect Dis. 2025 Apr 30:jiaf228. doi: 10.1093. PubMed
ATMAR RL, Lyke KE, Posavad CM, Deming ME, et al Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger
RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.
J Infect Dis. 2025 Apr 29:jiaf176. doi: 10.1093. PubMedAbstract available
CHEN H, Huang X, Wang C, Cowling BJ, et al Estimating the waning effectiveness of COVID-19 vaccines from population-level
surveillance data in Hong Kong.
J Infect Dis. 2025 Apr 18:jiaf207. doi: 10.1093. PubMedAbstract available
CORTIER T, Gilboa M, Layan M, Joseph G, et al Factors Associated With the Transmission of the Delta Severe Acute Respiratory
Syndrome Coronavirus 2 Variant in Households: The Israeli COVID-19 Family Study
(ICoFS).
J Infect Dis. 2025;231:e734-e742. PubMedAbstract available
GRAY P, Wang J, Nordqvist Kleppe S, Elfstrom KM, et al Population-Based Age-Period-Cohort Analysis of Declining Human Papillomavirus
Prevalence.
J Infect Dis. 2025;231:e638-e649. PubMedAbstract available
CHO HK, Frivold C, Chu HY Maternal Immunization.
J Infect Dis. 2025;231:830-836. PubMedAbstract available
YAMAMOTO S, Mizoue T, Ujiie M, Horii K, et al Low levels of post-vaccination hemagglutination inhibition antibodies and their
correlation with influenza protection among healthcare workers during the
2024/2025 A/H1N1 outbreak in Japan.
J Infect Dis. 2025 Apr 10:jiaf183. doi: 10.1093. PubMedAbstract available
LEWIS NM, Harker EJ, Cleary S, Zhu Y, et al Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated
Hospitalizations-United States, September 1, 2023-May 31, 2024.
J Infect Dis. 2025 Apr 8:jiaf185. doi: 10.1093. PubMedAbstract available
March 2025
WALSH EE, Peasley M, Branche A, Falsey AR, et al Respiratory Syncytial Virus (RSV) Humoral Antibody Responses in Older Adults
after Vaccination or Infection.
J Infect Dis. 2025 Mar 24:jiaf149. doi: 10.1093. PubMedAbstract available
ROSTAD CA, Campbell JD, Paulsen GC, Schnyder Ghamloush S, et al Evaluation of Cellular Immune Responses After mRNA-1273 Vaccination in Children 6
Months to 11 Years of Age.
J Infect Dis. 2025 Mar 22:jiaf144. doi: 10.1093. PubMedAbstract available
FUJI N, Salamone FN, Kaur R, Bajorski P, et al Eighteen Year Longitudinal Study of Uncomplicated and Complex Acute Otitis Media
during the Pneumococcal Conjugate Vaccine Era, 2006-2023.
J Infect Dis. 2025 Mar 20:jiaf154. doi: 10.1093. PubMedAbstract available
MENG Y, Lin Y, Xiong W, Lau EHY, et al Effective Real-time Transmission Estimations Incorporating Population Viral Load
Distributions Amid SARS-CoV-2 Variants and Preexisting Immunity.
J Infect Dis. 2025;231:684-691. PubMedAbstract available
DASS S, Kundu P, Naskar D, Kanjee U, et al Miniaturized assay to evaluate Plasmodium cynomolgi and P. knowlesi as models for
prioritizing P. vivax vaccine targets.
J Infect Dis. 2025 Mar 14:jiaf136. doi: 10.1093. PubMedAbstract available
HEDBERG P, van der Werff SD, Naucler P The effect of COVID-19 vaccination on the risk of persistent post COVID-19
condition: Cohort study.
J Infect Dis. 2025 Mar 12:jiaf133. doi: 10.1093. PubMedAbstract available
CHESSON HW, Markowitz LE Strong Herd Effects of Human Papillomavirus Vaccination.
J Infect Dis. 2025 Mar 5:jiaf121. doi: 10.1093. PubMed
February 2025
WONG A, Warren JL, Fitch L, Perniciaro S, et al Estimating the serotype-specific association between the concentration of
vaccine-induced serum antibodies and protection against pneumococcal
colonization.
J Infect Dis. 2025 Feb 28:jiaf106. doi: 10.1093. PubMedAbstract available
XU X, Ray I, Tang E, Arnold BF, et al Protective Effects of Recombinant Zoster Vaccine and Antiviral Therapy Against
Cardiovascular Disease Following Herpes Zoster Infection.
J Infect Dis. 2025 Feb 28:jiaf105. doi: 10.1093. PubMedAbstract available
GRANT LR, Sutcliffe CG, Littlepage S, Alexander-Parrish R, et al Persistence of vaccine serotype carriage and differences in pneumococcal carriage
by lab method and sample type in Indigenous individuals in the Southwest USA.
J Infect Dis. 2025 Feb 26:jiaf091. doi: 10.1093. PubMedAbstract available
SMITH WB, Seger W, Chawana R, Jefferies Z, et al A Phase 2b Trial Evaluating the Safety, Tolerability, and Immunogenicity of a
6-Valent Group B Streptococcus Vaccine Administered Concomitantly With Tetanus,
Diphtheria, and Acellular Pertussis Vaccine in Healthy Nonpregnant Female
Individuals.
J Infect Dis. 2025 Feb 26:jiaf096. doi: 10.1093. PubMedAbstract available
KANBAYASHI D, Kurata T, Kaida Y, Miyoshi T, et al How to Prevent Rubella Epidemics and Congenital Rubella Syndrome: Lessons From 42
Years of Longitudinal Epidemiology in Osaka Prefecture, Japan (1982-2023).
J Infect Dis. 2025;231:440-450. PubMedAbstract available
Correction to: Natural Boosting and the Immunogenicity of the XBB.1.5 Monovalent
Vaccine in the Coronavirus Disease 2019 Endemic Era: A Longitudinal Observational
Study.
J Infect Dis. 2025 Feb 17:jiaf073. doi: 10.1093. PubMed
SOTO G, Romero C, Gonzales M, La Rosa S, et al Influenza Virus Surveillance in Healthcare Personnel in Peru: NAMRU SOUTH
Experience and Perspective.
J Infect Dis. 2025;231. PubMedAbstract available
KOLLMANN TR, Amenyogbe N, Schaltz-Buchholzer F, Baek O, et al Is systemic dissemination of BCG following neonatal vaccination required for
protection against M. tuberculosis?
J Infect Dis. 2025 Feb 6:jiaf051. doi: 10.1093. PubMedAbstract available
BARTHOLDSSON S, Hergens MP, Hansson KE, Ragnarsson J, et al Clinical Characteristics of Tick-Borne Encephalitis in Adult Patients: A 10-year
Retrospective Study in Stockholm, Sweden.
J Infect Dis. 2025;231:e195-e205. PubMedAbstract available
PISANIC N, Antar AAR, Hetrich MK, Demko ZO, et al Early, Robust Mucosal Secretory Immunoglobulin A but not Immunoglobulin G
Response to Severe Acute Respiratory Syndrome Coronavirus 2 Spike in Oral Fluid
Is Associated With Faster Viral Clearance and Coronavirus Disease 2019 Symptom
Resolution.
J Infect Dis. 2025;231:121-130. PubMedAbstract available
EL SAFADI D, Hitchins L, Howard A, Aley P, et al Pneumococcal Carriage and Disease in Adults in England, 2011-2019: The Importance
of Adults as a Reservoir for Pneumococcus in Communities.
J Infect Dis. 2025;231:e17-e27. PubMedAbstract available
JARA JH, Loayza S, Nogareda F, Couto P, et al Influenza vaccine averted illnesses in Chile, Guyana, and Paraguay during
2013-2018: a standardized approach to assess value of vaccination.
J Infect Dis. 2025 Feb 1:jiaf038. doi: 10.1093. PubMedAbstract available
DESCALZO MA, de Paula Junior FJ, Mallegas NV, Penayo E, et al Annual estimation of seasonal influenza burden in six South American countries: a
retrospective analysis of SARInet surveillance data to inform policies.
J Infect Dis. 2025 Feb 1:jiaf037. doi: 10.1093. PubMedAbstract available
January 2025
LAURENS MB Controlled human infection studies accelerate vaccine development.
J Infect Dis. 2025 Jan 29:jiaf053. doi: 10.1093. PubMedAbstract available
ASTORGA ALSINA AM, Herweijer E, Lei J Population-level Impact of HPV Vaccination on the Incidence of Genital Warts in
Sweden.
J Infect Dis. 2025 Jan 29:jiaf052. doi: 10.1093. PubMedAbstract available
COOPER LV, Bandyopadhyay AS, Grassly NC, Gray EJ, et al Global Impact of Mass Vaccination Campaigns on Circulating Type 2 Vaccine-Derived
Poliovirus Outbreaks: An Interrupted Time-Series Analysis.
J Infect Dis. 2025 Jan 28:jiae614. doi: 10.1093. PubMedAbstract available
OLAL C, Bodmer BS, Rottstegge M, Escudero-Perez B, et al Antibody-Based Antigen Delivery to Dendritic Cells as a Vaccination Strategy
Against Ebola Virus Disease.
J Infect Dis. 2025 Jan 14:jiae613. doi: 10.1093. PubMedAbstract available
PICHICHERO ME, Gonzalez E, Cox A, Thayer TC, et al Variability in Vaccine Response and Trajectory in Early Childhood and Association
with Demographic Variables, Antibiotic Exposure and Infection Proneness.
J Infect Dis. 2025 Jan 11:jiaf023. doi: 10.1093. PubMedAbstract available
CHALKIAS S, Pragalos A, Akinsola A, Berman G, et al Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain
andN-Terminal Domain mRNA Vaccine.
J Infect Dis. 2025 Jan 10:jiaf022. doi: 10.1093. PubMedAbstract available
BILLINGS WZ, Ge Y, Knight JH, Hemme H, et al High dose inactivated influenza vaccine inconsistently improves heterologous
antibody responses in an elderly human cohort.
J Infect Dis. 2025 Jan 8:jiaf003. doi: 10.1093. PubMedAbstract available
FELDSTEIN LR, Ruffin J, Wiegand RE, Borkowf CB, et al Effectiveness of mRNA COVID-19 vaccines and hybrid immunity in preventing
SARS-CoV-2 infection and symptomatic COVID-19 among adults in the United States.
J Infect Dis. 2025 Jan 8:jiaf007. doi: 10.1093. PubMedAbstract available
December 2024
BALIBAN SM, Shridhar S, Luo K, Kolasny J, et al A core glycolipid vaccine elicits cross-reactive antibodies against Salmonella
spp. and protects against invasive nontyphoidal Salmonella disease in mice.
J Infect Dis. 2024 Dec 31:jiae641. doi: 10.1093. PubMedAbstract available
CHANDRASEKARAN P, Berry IM, Callier V, Anthony SM, et al Vector induced humoral responses after rVSVDeltaG-ZEBOV-GP immunization identify
vaccinated individuals and correlate with Ebola virus glycoprotein antibodies.
J Infect Dis. 2024 Dec 24:jiae632. doi: 10.1093. PubMedAbstract available
FORCADELL-PERIS MJ, Vila-Corcoles A, de Diego-Cabanes C, Torras Vives V, et al Evaluating Sex Differences in Pneumococcal Disease Burden and Vaccination
Effectiveness in Adults: A Population-Based Study.
J Infect Dis. 2024 Dec 16:jiae624. doi: 10.1093. PubMedAbstract available
ATMAR RL, Ettayebi K, Neill FH, Braun RP, et al Correlation of Genogroup I, Genotype 1 (GI.1) Norovirus Neutralizing Antibody
Levels With GI.1 Histo-Blood Group Antigen-Blocking Antibody Levels.
J Infect Dis. 2024;230:1376-1379. PubMedAbstract available
CHAN JCH, Leung D, Chan SM, Tam IYS, et al Seroepidemiology of Measles and Rubella Among Hong Kong Young Adults and the
Humoral Responses of a Measles-Mumps-Rubella Booster Among Participants With Low
Antibody Levels.
J Infect Dis. 2024;230:1367-1375. PubMedAbstract available
HAMMERTON SM, Billings WZ, Hemme H, Ross TM, et al Estimating standard-dose and high-dose Fluzone vaccine efficacies for influenza A
based on HAI titers.
J Infect Dis. 2024 Dec 13:jiae615. doi: 10.1093. PubMedAbstract available
WILSON GJ, Church LWP, Kelley CF, Robinson ST, et al HVTN 123: A Phase 1, Randomized Trial Comparing Safety and Immunogenicity of
CH505TF gp120 Produced by Stably and Transiently Transfected Cell Lines.
J Infect Dis. 2024 Dec 13:jiae558. doi: 10.1093. PubMedAbstract available
November 2024
KANG HM, Kim HJ, Jung J, Ahn JY, et al Natural Boosting and the Immunogenicity of the XBB.1.5 Monovalent Vaccine in the
Coronavirus Disease 2019 Endemic Era: A Longitudinal Observational Study.
J Infect Dis. 2024 Nov 29:jiae536. doi: 10.1093. PubMedAbstract available
BURNETT E, Umana J, Anwari P, Mujuru HA, et al Rotavirus vaccine effectiveness stratified by national-level characteristics: an
introduction to the 24-country MNSSTER-V Project, 2007-2023.
J Infect Dis. 2024 Nov 28:jiae597. doi: 10.1093. PubMedAbstract available
Expression of Concern: Relative Effectiveness and Waning of a Third Dose of mRNA
COVID-19 Vaccine in Medicare Beneficiaries Aged 65 Years and Older during the
BA.1/BA.2 Omicron Period.
J Infect Dis. 2024 Nov 28:jiae549. doi: 10.1093. PubMed
Correction to: Half-life Estimation of Pertussis-Specific Maternal Antibodies in
(Pre)Term Infants After In-Pregnancy Tetanus, Diphtheria, Acellular Pertussis
Vaccination.
J Infect Dis. 2024 Nov 25:jiae565. doi: 10.1093. PubMed
LEE AR, Kim WJ, Choi H, Kim SH, et al Genotype III-Based Japanese Encephalitis Vaccines Exhibit Diminished Neutralizing
Response to Re-emerging Genotype V.
J Infect Dis. 2024 Nov 22:jiae589. doi: 10.1093. PubMedAbstract available
ZHAI PY, Zang X, Jiang T, Feng J, et al Health and Economic Impacts of Introducing Vaccae and Enhanced Drug-Resistant
Tuberculosis Management Strategies in China.
J Infect Dis. 2024 Nov 22:jiae590. doi: 10.1093. PubMedAbstract available
NYGARD S, Falkenthal T, Sture T, Lynge E, et al Impact of multi-cohort HPV vaccination on cervical cancer in women below 30 years
of age: Lessons learned from the Scandinavian countries.
J Infect Dis. 2024 Nov 21:jiae584. doi: 10.1093. PubMedAbstract available
Correction to: Safety and Immunogenicity of a 4-Component Generalized Modules for
Membrane Antigens Shigella Vaccine in Healthy European Adults: Randomized, Phase
1/2 Study.
J Infect Dis. 2024 Nov 20:jiae564. doi: 10.1093. PubMed
KAUR R, Gierke R, McGee L, Gonzalez E, et al Pneumococci Isolated From Children in Community-Based Practice Differ From
Isolates Identified by Population- and Laboratory-Based Invasive Disease
Surveillance.
J Infect Dis. 2024;230:1243-1252. PubMedAbstract available
COHEN C, du Plessis M, Martinson N, Moyes J, et al A potential platform for future vaccine trials identifies high incidence of
symptomatic and asymptomatic influenza infection among children aged 6-23 months
in South Africa.
J Infect Dis. 2024 Nov 14:jiae550. doi: 10.1093. PubMedAbstract available
HUANG X, Wu J, Xu J, Wang H, et al Mycobacterium tuberculosis Antigen Rv1471 Induces Innate Immune Memory and
Adaptive Immunity against Infection.
J Infect Dis. 2024 Nov 14:jiae572. doi: 10.1093. PubMedAbstract available
MAK J, Khan S, Britton A, Rose S, et al Association of mRNA COVID-19 vaccination and reductions in Post-COVID Conditions
following SARS-CoV-2 infection in a US prospective cohort of essential workers.
J Infect Dis. 2024 Nov 13:jiae556. doi: 10.1093. PubMedAbstract available
WATKINS TA, Brockhurst JK, Germain G, Griffin DE, et al Detection of live attenuated measles virus in the respiratory tract following
subcutaneous MMR Vaccination.
J Infect Dis. 2024 Nov 6:jiae537. doi: 10.1093. PubMedAbstract available
YEGOROV S, Brewer A, Cyr L, Ward BJ, et al Hemagglutination-Inhibition Antibodies and Protection against Influenza Elicited
by Inactivated and Live Attenuated Vaccines in Children.
J Infect Dis. 2024 Nov 6:jiae489. doi: 10.1093. PubMedAbstract available
October 2024
LEROUX-ROELS I, Alhatemi A, Caubet M, De Boever F, et al Safety and Immunogenicity of an Adjuvanted Clostridioides difficile Vaccine
Candidate in Healthy Adults: A Randomized Placebo-Controlled Phase 1 Study.
J Infect Dis. 2024 Oct 24:jiae466. doi: 10.1093. PubMedAbstract available
YOON KW, Chu KB, Eom GD, Mao J, et al CpG-adjuvanted virus-like particle vaccine induces protective immunity against
Leishmania donovani infection.
J Infect Dis. 2024 Oct 24:jiae526. doi: 10.1093. PubMedAbstract available
MAVIAN CN, Tagliamonte MS, Bassett M, Alam M, et al COVID-19 lineages in a minimally vaccinated island population: Genomic
epidemiology of SARS-CoV-2 in Haiti.
J Infect Dis. 2024 Oct 23:jiae520. doi: 10.1093. PubMedAbstract available
DIB SM, Tandon Wimalasena S, Graciaa DS, Rouphael N, et al Systems Vaccinology: Navigating the Future of Personalized Immunity and Next
Generation Vaccines.
J Infect Dis. 2024 Oct 19:jiae505. doi: 10.1093. PubMedAbstract available
KNISELY JM, Erbelding E Vaccines for Global Health: Progress and Challenges.
J Infect Dis. 2024 Oct 18:jiae511. doi: 10.1093. PubMed
SELVERIAN CN, Monticelli SR, Jaleta YM, Lasso G, et al MPXV Infection Stimulates a More Robust and Durable Neutralizing Antibody
Response Compared to MVA-BN Vaccination.
J Infect Dis. 2024 Oct 18:jiae515. doi: 10.1093. PubMedAbstract available
BABU TM, Jackson LA, El Sahly HM Next-Generation SARS-CoV-2 Vaccine Formulations and Alternative Routes of
Administration.
J Infect Dis. 2024 Oct 16:jiae504. doi: 10.1093. PubMedAbstract available
SCHALTZ-BUCHHOLZER F, Nielsen S, Sorensen MK, Gomes GM, et al Maternal Bacille Calmette-Guerin Scars and Mortality Risk for Male and Female
Newborns: Observational Study From Guinea-Bissau.
J Infect Dis. 2024;230:995-1003. PubMedAbstract available
HAGER DN, Zhu Y, Sohn I, Stubblefield WB, et al Effectiveness of the original monovalent mRNA COVID-19 vaccination series against
hospitalization for COVID-19-associated venous thromboembolism.
J Infect Dis. 2024 Oct 15:jiae502. doi: 10.1093. PubMedAbstract available
LU Y, Matuska K, McEvoy R, Izurieta HS, et al Relative Effectiveness and Waning of a Third Dose of mRNA COVID-19 Vaccine in
Medicare Beneficiaries Aged 65 Years and Older during the BA.1/BA.2 Omicron
Period.
J Infect Dis. 2024 Oct 15:jiae503. doi: 10.1093. PubMedAbstract available
OKOLI GN, Cowling BJ Improved Methods for Vaccine Effectiveness Studies.
J Infect Dis. 2024 Oct 15:jiae510. doi: 10.1093. PubMedAbstract available
ISON MG Vaccines for Use in Special Populations: Immunocompromised Hosts.
J Infect Dis. 2024 Oct 15:jiae508. doi: 10.1093. PubMed
DOBRZYNSKI D, Branche AR, Falsey AR Combination seasonal vaccines for influenza, RSV, SARS-CoV-2, and other
pathogens.
J Infect Dis. 2024 Oct 15:jiae507. doi: 10.1093. PubMed
CHU HY A Perspective on Vaccinology.
J Infect Dis. 2024 Oct 14:jiae506. doi: 10.1093. PubMed
LANGWORTHY K, Taggart M, Smith R, Levy A, et al Serological responses to target Streptococcus pyogenes vaccine antigens in
patients with proven invasive beta-haemolytic streptococcal infections.
J Infect Dis. 2024 Oct 9:jiae496. doi: 10.1093. PubMedAbstract available
YAO T, Li Y, Zhang Y, Sun Y, et al Immunogenicity, safety, and persistence induced by triple- and standard-strength
four-dose hepatitis B vaccination regimens in hemodialysis patients: A
multicenter, randomized, parallel-controlled trial in Six cities in Shanxi
Province.
J Infect Dis. 2024 Oct 8:jiae494. doi: 10.1093. PubMedAbstract available
BUTT AA, Yan P, Abou-Samra AB, Shaikh OS, et al COVID-19 Disease Incidence and Severity in Previously Infected Unvaccinated
Compared with Previously Uninfected Vaccinated Persons.
J Infect Dis. 2024 Oct 8:jiae484. doi: 10.1093. PubMedAbstract available
DU QQ, Shi W, Yao KH Pneumococcal Disease Research Across All Age Groups: Advancing Comprehensive
Vaccination Strategies.
J Infect Dis. 2024 Oct 5:jiae483. doi: 10.1093. PubMed
PUN J, Evans C, Chasekwa B, Church JA, et al Associations between Histo-Blood Group Antigen Status in Mother-Infant Dyads and
Infant Oral Rotavirus Vaccine Immunogenicity in rural Zimbabwe.
J Infect Dis. 2024 Oct 1:jiae456. doi: 10.1093. PubMedAbstract available
September 2024
MURUGAIAH V, Watson SJ, Cunliffe RF, Temperton NJ, et al A transgenic mouse with a humanised B cell repertoire mounts an antibody response
to influenza infection and vaccination.
J Infect Dis. 2024 Sep 24:jiae472. doi: 10.1093. PubMedAbstract available
NGUYEN HC, Lal KG, Balinsky CA, Hontz RD, et al Informing the Need for a SARS-CoV-2 Booster Based on the Immune Responses Among
Young Healthy Adults to Variants Circulating in Late 2023.
J Infect Dis. 2024;230:645-656. PubMedAbstract available
SALEEM AF, Kazi ZU, Zehra SM, Parkar S, et al Mucosal Immunity to Poliovirus in Children 0-15 Years of Age: A Community-Based
Study in Karachi, Pakistan in 2019.
J Infect Dis. 2024;230:736-740. PubMedAbstract available
LIN LY, Gantner P, Li S, Su B, et al Unpredicted protective function of Fc-mediated inhibitory antibodies for HIV and
SARS-CoV-2 vaccines.
J Infect Dis. 2024 Sep 20:jiae464. doi: 10.1093. PubMedAbstract available
BAHAKEL H, Spieker AJ, Hayek H, Schuster JE, et al Immunogenicity and Reactogenicity of High-dose or Standard-dose Influenza Vaccine
in a Second Consecutive Influenza Season.
J Infect Dis. 2024 Sep 16:jiae454. doi: 10.1093. PubMedAbstract available
KUSTERS JMA, Schim van der Loeff MF, Heijne JCM, King AJ, et al Changes in Genital HPV Prevalence during 12 Years Girls-Only Bivalent HPV
Vaccination: Results from a Biennial Repeated Cross-Sectional Study.
J Infect Dis. 2024 Sep 13:jiae455. doi: 10.1093. PubMedAbstract available
TANG Y, Boribong BP, Swank ZN, Demokritou M, et al COVID-19 mRNA vaccines induce robust levels of IgG but limited amounts of IgA
within the oronasopharynx of young children.
J Infect Dis. 2024 Sep 10:jiae450. doi: 10.1093. PubMedAbstract available
MUNYEMANA JB, Kabayiza JC, Nilsson S, Andersson ME, et al Shigella and ETEC have replaced rotavirus as main causes of childhood diarrhea in
Rwanda after ten years of rotavirus vaccination.
J Infect Dis. 2024 Sep 9:jiae446. doi: 10.1093. PubMedAbstract available
JANES H, Fisher LH, Kee JJ, Parameswaran L, et al Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3
Trials.
J Infect Dis. 2024 Sep 3:jiae400. doi: 10.1093. PubMedAbstract available
August 2024
BALGOVIND P, Aung E, Shilling H, Murray GL, et al Human papillomavirus prevalence among Australian men aged 18-35 years in
2015-2018 according to vaccination status and sexual preference.
J Infect Dis. 2024 Aug 30:jiae412. doi: 10.1093. PubMedAbstract available
SALAZAR JC, Radolf JD T-Cell Responses to Treponema pallidum Proteins in Blood and Skin to Advance
Syphilis Vaccine Design: Learning From Nature.
J Infect Dis. 2024;230:275-277. PubMed
GOH YS, Fong SW, Hor PX, Loh CY, et al Variant-Specific IgA Protects Against Omicron Infection.
J Infect Dis. 2024;230:e287-e291. PubMedAbstract available
MARCHESE AM, Rousculp M, Macbeth J, Beyhaghi H, et al The Novavax Heterologous Coronavirus Disease 2019 Booster Demonstrates Lower
Reactogenicity Than Messenger RNA: A Targeted Review.
J Infect Dis. 2024;230:e496-e502. PubMedAbstract available
JOHNSON EE, Hart TM, Fikrig E Vaccination to Prevent Lyme Disease: A Movement Towards Anti-Tick Approaches.
J Infect Dis. 2024;230. PubMedAbstract available
DESISTO CL, Winer RL, Querec TD, Dada D, et al Vaccine effectiveness against anal HPV among men who have sex with men aged 18-45
years attending sexual health clinics in three United States cities, 2018-2023.
J Infect Dis. 2024 Aug 8:jiae394. doi: 10.1093. PubMedAbstract available
CHOCHUA S, Beall B, Lin W, Tran T, et al The emergent invasive serotype 4 ST10172 strain acquires vanG type
vancomycin-resistance element: A case of a 66-year-old with bacteremic
pneumococcal pneumonia.
J Infect Dis. 2024 Aug 8:jiae393. doi: 10.1093. PubMedAbstract available
LEWNARD JA, Hong V, Grant LR, Ackerson BK, et al Association of pneumococcal conjugate vaccination with SARS-CoV-2 infection among
older adult recipients of COVID-19 vaccines: a longitudinal cohort study.
J Infect Dis. 2024 Aug 5:jiae387. doi: 10.1093. PubMedAbstract available
July 2024
ABARA WE, Kirkcaldy RD, Bernstein KT, Galloway E, et al Effectiveness of MenB-4C vaccine against gonorrhea: a systematic review and
meta-analysis.
J Infect Dis. 2024 Jul 31:jiae383. doi: 10.1093. PubMedAbstract available
Correction to: Interim Report of the Reactogenicity and Immunogenicity of Severe
Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines.
J Infect Dis. 2024;230:e219. PubMed
CLARK RA, Sumner T, Weerasuriya CK, Bakker R, et al Estimating the Potential Public Health Value of BCG Revaccination.
J Infect Dis. 2024;230:e139-e143. PubMedAbstract available
HORN EK, Herrera-Restrepo O, Acosta AM, Simon A, et al The Burden of Hepatitis A Outbreaks in the United States: Health Outcomes,
Economic Costs, and Management Strategies.
J Infect Dis. 2024;230:e199-e218. PubMedAbstract available
LIM WW, Feng S, Wong SS, Sullivan SG, et al Hemagglutination Inhibition Antibody Titers as Mediators of Influenza Vaccine
Efficacy Against Symptomatic Influenza A(H1N1), A(H3N2), and B/Victoria Virus
Infections.
J Infect Dis. 2024;230:152-160. PubMedAbstract available
KALIZANG'OMA A, Swarthout TD, Mwalukomo TS, Kamng'ona A, et al Clonal Expansion of a Streptococcus pneumoniae Serotype 3 Capsule Variant
Sequence Type 700 With Enhanced Vaccine Escape Potential After 13-Valent
Pneumococcal Conjugate Vaccine Introduction.
J Infect Dis. 2024;230:e189-e198. PubMedAbstract available
SCHWARZ TF, Hwang SJ, Ylisastigui P, Liu CS, et al Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory
Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial.
J Infect Dis. 2024;230:e102-e110. PubMedAbstract available
TENFORDE MW, Weber ZA, Yang DH, DeSilva MB, et al Influenza Vaccine Effectiveness Against Influenza A-Associated Emergency
Department, Urgent Care, and Hospitalization Encounters Among US Adults,
2022-2023.
J Infect Dis. 2024;230:141-151. PubMedAbstract available
SUMNER KM, Yadav R, Noble EK, Sandford R, et al Anti-SARS-CoV-2 Antibody Levels Associated With COVID-19 Protection in
Outpatients Tested for SARS-CoV-2, US Flu Vaccine Effectiveness Network, October
2021-June 2022.
J Infect Dis. 2024;230:45-54. PubMedAbstract available
FELL DB, Russell M, Fung SG, Swayze S, et al Effectiveness of Influenza Vaccination During Pregnancy Against
Laboratory-Confirmed Seasonal Influenza Among Infants Under 6 Months of Age in
Ontario, Canada.
J Infect Dis. 2024;230:e80-e92. PubMedAbstract available
BENNETT C, Rivers EJ, Woo W, Bloch M, et al Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2
Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial.
J Infect Dis. 2024;230:e4-e16. PubMedAbstract available
JEAN BAPTISTE AE, Wagai J, Hahne S, Adeniran A, et al High-Resolution Geospatial Mapping of Zero-Dose and Underimmunized Children
Following Nigeria's 2021 Multiple Indicator Cluster Survey/National Immunization
Coverage Survey.
J Infect Dis. 2024;230:e131-e138. PubMedAbstract available
LEE K, Williams KV, Englund JA, Sullivan SG, et al The Potential Benefits of Delaying Seasonal Influenza Vaccine Selections for the
Northern Hemisphere: A Retrospective Modeling Study in the United States.
J Infect Dis. 2024;230:131-140. PubMedAbstract available
CHONG EA, Kumashie KG, Chong ER, Fabrizio J, et al Immunologic Predictors of Vaccine Responsiveness in Patients With Lymphoma and
Chronic Lymphocytic Leukemia.
J Infect Dis. 2024;230:15-27. PubMedAbstract available
CISZEWSKI J, Taniuchi M, Lee B, Colgate ER, et al Differences in Rotavirus Shedding and Duration by Infant Oral Rotavirus
Vaccination Status in Dhaka, Bangladesh, 2011-2014.
J Infect Dis. 2024;230:e75-e79. PubMedAbstract available
ALESSANDRINI J, Cox J, de Pokomandy A, Hart TA, et al Prevalence of Oral Human Papillomavirus Infection Among Urban Gay, Bisexual, and
Other Men Who Have Sex With Men in Canada, 2017-2019.
J Infect Dis. 2024 Jul 23:jiae345. doi: 10.1093. PubMedAbstract available
BLOOM N, Ramirez SI, Cohn H, Parikh UM, et al SARS-CoV-2 monoclonal antibody treatment followed by vaccination shifts human
memory B cell epitope recognition suggesting antibody feedback.
J Infect Dis. 2024 Jul 22:jiae371. doi: 10.1093. PubMedAbstract available
LACABARATZ C, Durand M, Wiedemann A, Foucat E, et al Innate and cellular immune response to the Ebola vaccine Ad26.ZEBOV, MVA-BN-Filo:
an ancillary study of the EBL2001 phase II trial.
J Infect Dis. 2024 Jul 16:jiae360. doi: 10.1093. PubMedAbstract available
HILL-BATORSKI L, Weiner JA, Ackerman ME, Hatta Y, et al Intranasal M2SR (M2-deficient Single Replication) Influenza Vaccine Induces
Broadly Reactive Mucosal Antibody Production in Adults.
J Infect Dis. 2024 Jul 16:jiae361. doi: 10.1093. PubMedAbstract available
GALAFA B, Chikaonda T, Kudowa E, Sichone S, et al Natural carriage of Streptococcus pneumoniae is associated with increased
experimental pneumococcal carriage but reduced conjugate vaccine efficacy in a
human challenge model.
J Infect Dis. 2024 Jul 10:jiae341. doi: 10.1093. PubMedAbstract available
CHIME N, Anspach B, Jain V, Laajalahti O, et al Phase 3 Study Assessing Lot-to-lot Consistency of RSVPreF3 Vaccine and its Immune
Response, Safety, and Reactogenicity When Co-administered with FLU-D-QIV.
J Infect Dis. 2024 Jul 5:jiae342. doi: 10.1093. PubMedAbstract available
Correction to: Antibody Levels and Protection After Hepatitis B Vaccine: Results
of a 30-Year Follow-up Study and Response to a Booster Dose.
J Infect Dis. 2024 Jul 3:jiae336. doi: 10.1093. PubMed
MCCARRON M, Yau TS, Griffin C, Marcenac P, et al Do pregnant persons want influenza vaccines? Knowledge, attitudes, perceptions,
and practices toward influenza vaccines in 8 low- and middle-income countries.
J Infect Dis. 2024 Jul 2:jiae340. doi: 10.1093. PubMedAbstract available
Correction to: Progress in Access and Oral Polio Vaccine Coverage Among Children
Aged <5 Years in Polio Campaigns After the Political Change in Afghanistan.
J Infect Dis. 2024 Jul 1:jiae334. doi: 10.1093. PubMed
June 2024
ANANWORANICH J, Lee IT, Ensz D, Carmona L, et al Safety and Immunogenicity of mRNA-1010, an Investigational Seasonal Influenza
Vaccine, in Healthy Adults: Final Results From a Phase 1/2 Randomized Trial.
J Infect Dis. 2024 Jun 27:jiae329. doi: 10.1093. PubMedAbstract available
GOSWAMI J, Baqui AH, Doreski PA, Perez Marc G, et al Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults.
J Infect Dis. 2024 Jun 18:jiae316. doi: 10.1093. PubMedAbstract available
LACOURSE SM, Wetzler EA, Aurelio MC, Escudero JN, et al Hybrid Immunity to SARS-CoV-2 During Pregnancy Provides More Durable Infant
Antibody Responses Compared to Natural Infection Alone.
J Infect Dis. 2024;229:1728-1739. PubMedAbstract available
LEROUX-ROELS I, Maes C, Mancini F, Jacobs B, et al Safety and immunogenicity of a 4-component GMMA-based Shigella vaccine in healthy
European adults: Stage 1 of a randomized, controlled phase I/II clinical trial.
J Infect Dis. 2024 Jun 10:jiae273. doi: 10.1093. PubMedAbstract available
AMSTUTZ A, Chammartin F, Audige A, Eichenberger AL, et al Antibody and T-cell response to bivalent booster SARS-CoV-2 vaccines in people
with compromised immune function (COVERALL-3).
J Infect Dis. 2024 Jun 7:jiae291. doi: 10.1093. PubMedAbstract available
May 2024
RUIZ GARCIA Y, Marrazzo J, Martinon-Torres F, Workowski K, et al Urgent Need to Understand and Prevent Gonococcal Infection: From the Laboratory
to Real-World Context.
J Infect Dis. 2024 May 31:jiae289. doi: 10.1093. PubMedAbstract available
GODIN A, Connor RI, Degefu HN, Rosato PC, et al Nasal and pharyngeal mucosal immunity to poliovirus in children following routine
immunization with inactivated polio vaccine (IPV) in the United States of
America.
J Infect Dis. 2024 May 29:jiae264. doi: 10.1093. PubMedAbstract available
TOWNSEND L, Gillespie P, McGrath J, Kenny C, et al Health Care Personnel Workdays Lost and Direct Health Care Salary Costs Incurred
due to COVID-19 Infection in the Age of Widespread Vaccine Availability.
J Infect Dis. 2024 May 21:jiae223. doi: 10.1093. PubMedAbstract available
NJIFON HLM, Kenmoe S, Ahmed SM, Roussel Takuissu G, et al Epidemiology of Rotavirus in Humans, Animals, and the Environment in Africa: A
Systematic Review and Meta-analysis.
J Infect Dis. 2024;229:1470-1480. PubMedAbstract available
LEE YS, Bang YJ, Yoo S, Park SI, et al Analysis of the Immunostimulatory Effects of Cytokine-Expressing Internal
Ribosome Entry Site-Based RNA Adjuvants and Their Applications.
J Infect Dis. 2024;229:1408-1418. PubMedAbstract available
SMITH CL, Didion E, Aung H, Tamilselvan B, et al Longitudinal analysis of nursing home residents' T cell responses after
SARS-CoV-2 mRNA vaccinations shows influence of biological sex and SARS-CoV-2
infection history.
J Infect Dis. 2024 May 14:jiae234. doi: 10.1093. PubMedAbstract available
MOTSOENENG BM, Dhar N, Nunes MC, Krammer F, et al Hemagglutinin stalk-specific Fc-mediated functions are associated with protection
against influenza-illness after seasonal influenza vaccination in pregnant women.
J Infect Dis. 2024 May 14:jiae241. doi: 10.1093. PubMedAbstract available
PERSSON KEM, Horton JL, Kurtovic L, McCarthy JS, et al Declining antibody affinity over time after human vaccination with a Plasmodium
falciparum merozoite vaccine candidate.
J Infect Dis. 2024 May 9:jiae259. doi: 10.1093. PubMedAbstract available
HOY G, Stadlbauer D, Balmaseda A, Kuan G, et al Humoral correlates of protection against influenza A H3N2 virus infection.
J Infect Dis. 2024 May 9:jiae258. doi: 10.1093. PubMedAbstract available
EBINGER JE, Sun N, Joung SY, Sanchez JMS, et al Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Following Prior
Infection or Vaccination.
J Infect Dis. 2024 May 8:jiae130. doi: 10.1093. PubMedAbstract available
BALASINGAM S, Dheda K, Fortune S, Gordon SB, et al Review of the current TB human infection studies for use in accelerating TB
vaccine development: A meeting report.
J Infect Dis. 2024 May 6:jiae238. doi: 10.1093. PubMedAbstract available
April 2024
BI Q, Dickerman BA, Nguyen HQ, Martin ET, et al Reduced effectiveness of repeat influenza vaccination: distinguishing among
within-season waning, recent clinical infection, and subclinical infection.
J Infect Dis. 2024 Apr 30:jiae220. doi: 10.1093. PubMedAbstract available
JUHL AK, Lokso Dietz L, Schmeltz Sogaard O, Reekie J, et al Longitudinal evaluation of SARS-CoV-2 T cell immunity over 2 years following
vaccination and infection.
J Infect Dis. 2024 Apr 30:jiae215. doi: 10.1093. PubMedAbstract available
SIRIVICHAYAKUL C, Biswal S, Saez-Llorens X, Lopez-Medina E, et al Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With
Prior Japanese Encephalitis or Yellow Fever Vaccination.
J Infect Dis. 2024 Apr 29:jiae222. doi: 10.1093. PubMedAbstract available
ORUMAA M, Lahlum EJ, Gulla M, Tota J, et al Quadrivalent HPV vaccine effectiveness against cervical intraepithelial lesion
grade 2 or worse in Norway: A registry-based study of 0,9 million Norwegian
women.
J Infect Dis. 2024 Apr 25:jiae209. doi: 10.1093. PubMedAbstract available
Correction to: Interim Report of the Reactogenicity and Immunogenicity of Severe
Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines.
J Infect Dis. 2024 Apr 18:jiae186. doi: 10.1093. PubMed
NIKITIN D, Whittles LK, Imai-Eaton JW, White PJ, et al Cost-effectiveness of 4CMenB vaccination against gonorrhea: importance of dosing
schedule, vaccine sentiment, targeting strategy, and duration of protection.
J Infect Dis. 2024 Apr 17:jiae123. doi: 10.1093. PubMedAbstract available
COHEN MS, Marrazzo J What if We Had a Vaccine that Prevents Neisseria gonorrhoeae.
J Infect Dis. 2024 Apr 17:jiae160. doi: 10.1093. PubMed
WALSH EE, Falsey AR, Zareba AM, Jiang Q, et al Respiratory Syncytial Virus Prefusion F Vaccination: Antibody Persistence and
Revaccination.
J Infect Dis. 2024 Apr 12:jiae185. doi: 10.1093. PubMedAbstract available
UZZELL CB, Abraham D, Rigby J, Troman CM, et al Environmental Surveillance for Salmonella Typhi and its Association With Typhoid
Fever Incidence in India and Malawi.
J Infect Dis. 2024;229:979-987. PubMedAbstract available
SCHMIDT S, Mengistu M, Daffis S, Ahmadi-Erber S, et al Alternating Arenavirus Vector Immunization Generates Robust Polyfunctional
Genotype Cross-Reactive Hepatitis B Virus-Specific CD8 T-Cell Responses and High
Anti-Hepatitis B Surface Antigen Titers.
J Infect Dis. 2024;229:1077-1087. PubMedAbstract available
THOMPSON KM, Kalkowska DA, Routh JA, Brenner IR, et al Modeling Poliovirus Transmission and Responses in New York State.
J Infect Dis. 2024;229:1097-1106. PubMedAbstract available
SABAWOON W, Seino S, Pason BM, Momin NWS, et al Progress in Access and Oral Polio Vaccine Coverage Among Children Aged <5 Years
in Polio Campaigns After the Political Change in Afghanistan.
J Infect Dis. 2024 Apr 10:jiae129. doi: 10.1093. PubMedAbstract available
CHEN MH, Perelygina L, Hao L, Beard RS, et al Neutralization of Rubella Vaccine Virus and Immunodeficiency-Related
Vaccine-Derived Rubella Viruses by Intravenous Immunoglobulins.
J Infect Dis. 2024 Apr 9:jiae182. doi: 10.1093. PubMedAbstract available
PONZILACQUA-SILVA B, Dadelahi AS, Abushahba MFN, Moley CR, et al Vaccine Elicited Antibodies Restrict Glucose Availability to Control Brucella
Infection.
J Infect Dis. 2024 Apr 8:jiae172. doi: 10.1093. PubMedAbstract available
BARTSCH SM, O'Shea KJ, Weatherwax C, Strych U, et al What is the economic benefit of annual COVID-19 vaccination from the adult
individual perspective?
J Infect Dis. 2024 Apr 6:jiae179. doi: 10.1093. PubMedAbstract available
TAIT D, Diacon A, Borges AH, van Brakel E, et al Safety and immunogenicity of the H56:IC31 tuberculosis vaccine candidate in
adults successfully treated for drug-susceptible pulmonary TB: a phase 1
randomized trial.
J Infect Dis. 2024 Apr 1:jiae170. doi: 10.1093. PubMedAbstract available
March 2024
KAO CM, Rostad CA, Nolan LE, Peters E, et al A Phase 1, Double-blinded, Placebo-Controlled Clinical Trial to Evaluate the
Safety and Immunogenicity of HEV-239 (Hecolin(R)) Vaccine in Healthy US Adults.
J Infect Dis. 2024 Mar 27:jiae148. doi: 10.1093. PubMedAbstract available
KALIZANG'OMA A, Swarthout TD, Mwalukomo TS, Kamng'ona A, et al Clonal Expansion of a Streptococcus pneumoniae Serotype 3 Capsule Variant
Sequence Type 700 With Enhanced Vaccine Escape Potential After 13-Valent
Pneumococcal Conjugate Vaccine Introduction.
J Infect Dis. 2024 Mar 26:jiae040. doi: 10.1093. PubMedAbstract available
FIGUEROA AL, Azzi JR, Eghtesad B, Priddy F, et al Safety and Immunogenicity of the mRNA-1273 COVID-19 Vaccine in Solid Organ
Transplant Recipients.
J Infect Dis. 2024 Mar 21:jiae140. doi: 10.1093. PubMedAbstract available
PRUNAS O, Shioda K, Toscano CM, Bastias M, et al Estimated population-level impact of pneumococcal conjugate vaccines against
all-cause pneumonia mortality among unvaccinated age groups in five Latin
American countries.
J Infect Dis. 2024 Mar 19:jiae144. doi: 10.1093. PubMedAbstract available
KING LM, Andrejko KL, Kabbani S, Tartof SY, et al Outpatient visits and antibiotic use due to higher valency pneumococcal vaccine
serotypes.
J Infect Dis. 2024 Mar 18:jiae142. doi: 10.1093. PubMedAbstract available
PRASAD AN, Geisbert TW A glass-half-full perspective on negative data in Ebolavirus vaccine studies.
J Infect Dis. 2024 Mar 15:jiae109. doi: 10.1093. PubMed
VAN TOL S, Fletcher P, Feldmann F, Mukesh RK, et al A bivalent Adenovirus-Vectored Vaccine induces a robust humoral response, but
does not protect cynomolgus macaques against a lethal challenge with Sudan virus.
J Infect Dis. 2024 Mar 15:jiae056. doi: 10.1093. PubMedAbstract available
ROSSLER A, Knabl L, Netzl A, Bante D, et al Durability of Cross-Neutralizing Antibodies 5.5 Months After Bivalent Coronavirus
Disease 2019 Vaccine Booster.
J Infect Dis. 2024;229:644-647. PubMedAbstract available
GRUNER E, Grossegesse M, Stern D, Ober V, et al Mpox-specific immune responses elicited by vaccination or infection in people
living with HIV.
J Infect Dis. 2024 Mar 13:jiae138. doi: 10.1093. PubMedAbstract available
FIERRO C, Brune D, Shaw M, Schwartz H, et al Safety and Immunogenicity of a Messenger RNA-Based Cytomegalovirus Vaccine in
Healthy Adults: Results From a Phase 1, Randomized, Clinical Trial.
J Infect Dis. 2024 Mar 13:jiae114. doi: 10.1093. PubMedAbstract available
MUNK C, Reinholdt K, Kjaer AK, Hemmingsen CH, et al Prevalence of Human Papillomavirus (HPV) and HPV Type Distribution in Penile
Samples in Young Men in Denmark: Results 10 Years After Implementation of a
Girls-Only HPV Vaccination Program.
J Infect Dis. 2024 Mar 12:jiae068. doi: 10.1093. PubMedAbstract available
SEPULVEDA-PACHON IT, Dunne EM, Hanquet G, Baay M, et al Effect of pneumococcal conjugate vaccines on viral respiratory infections: a
systematic literature review.
J Infect Dis. 2024 Mar 11:jiae125. doi: 10.1093. PubMedAbstract available
LIM WW, Shuo F, Wong SS, Sullivan SG, et al Hemagglutination inhibition antibody titers mediate influenza vaccine efficacy
against symptomatic influenza A(H1N1), A(H3N2), and B/Victoria infections.
J Infect Dis. 2024 Mar 7:jiae122. doi: 10.1093. PubMedAbstract available
COLON W, Oriol Mathieu V, Hural J, Hattingh L, et al HIV Diagnostics and Vaccines: It Takes Two to Tango.
J Infect Dis. 2024 Mar 7:jiae113. doi: 10.1093. PubMedAbstract available
WESTERCAMP N, Osei-Tutu L, Schuerman L, Kariuki SK, et al Could less be more? Accounting for fractional-dose regimens and different number
of vaccine doses when measuring the impact of the RTS, S/AS01E malaria vaccine.
J Infect Dis. 2024 Mar 4:jiae075. doi: 10.1093. PubMedAbstract available
CHONG EA, Kumashie KG, Chong ER, Fabrizio J, et al Immunologic predictors of vaccine responsiveness in patients with lymphoma and
CLL.
J Infect Dis. 2024 Mar 4:jiae106. doi: 10.1093. PubMedAbstract available
February 2024
CAO Y, Hayashi CTH, Kumar N A novel ex vivo assay to evaluate functional effectiveness of Plasmodium vivax
transmission blocking vaccine using Pvs25 transgenic P. berghei.
J Infect Dis. 2024 Feb 26:jiae102. doi: 10.1093. PubMedAbstract available
WANTUCH PL, Knoot CJ, Robinson LS, Vinogradov E, et al A heptavalent O-antigen bioconjugate vaccine exhibits differential functional
antibody responses against diverse Klebsiella pneumoniae isolates.
J Infect Dis. 2024 Feb 24:jiae097. doi: 10.1093. PubMedAbstract available
DZIADULA J, Sabbaj S, Gupta K, Cutter G, et al Interferon-Gamma Responses to Chlamydia trachomatis Vaccine Candidate Proteins in
Chlamydia-Infected Women with Different Chlamydia Outcomes.
J Infect Dis. 2024 Feb 23:jiae092. doi: 10.1093. PubMedAbstract available
November 2023
BLAZEVIC A, Edwards RL, Xia M, Eickhoff CS, et al Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus
Calmette-Guerin Challenge Model for Assessment of Tuberculosis Immunity In Vivo.
J Infect Dis. 2023 Nov 29:jiad441. doi: 10.1093. PubMedAbstract available
GIULIANO AR, Palefsky JM, Goldstone SE, Dubin B, et al High Risk of New HPV Infection Acquisition Among Unvaccinated Young Men.
J Infect Dis. 2023 Nov 28:jiad485. doi: 10.1093. PubMedAbstract available